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Impulse control disorders (ICDs) and other impulsive-compulsive related behaviours are frequent and still under
recognized non-motor complications of Parkinson’s disease (PD). They result from sensitization of the
mesocorticolimbic pathway that arose in predisposed PD patients concomitantly with spreading of PD pathology,
non-physiological dopaminergic and pulsatile administration of dopamine replacement therapy (DRT).
Neuropsychiatric fluctuations (NPF) reflect the psychotropic effects of dopaminergic drugs and play a crucial role in
the emergence of ICDs and behavioral addictions. Dopamine agonists (DA) which selectively target D2 and D3
receptors mostly expressed within the mesocorticolimbic pathway, are the main risk factor to develop ICDs.
Neuroimaging studies suggest that dopamine agonists lead to a blunted response of the brain’s reward system
both during reward delivery and anticipation. Genetic predispositions are crucial for the responsiveness of the
mesolimbic system and the development of ICDs with several genes having been identified. Early screening for
neuropsychiatric fluctuations, reduction of DA, fractionating levodopa dosage, education of patients and their
relatives, are the key strategies for diagnosis and management of ICDs and related disorders.
Keywords: Parkinson’s disease, Impulse control disorders, Behavioral addictions, Dopamine, Neuropsychiatric
fluctuations, Mesocorticolimbic sensitizationBackground
Although motor signs namely bradykinesia, rigidity and
tremor are still considered as the core feature of diagnos-
tic criteria for Parkinson disease (PD) [71], increasing rec-
ognition has been given over time to non-motor
manifestations of PD including cognitive, autonomic, and
neuropsychiatric signs [99]. Neuropsychiatric signs refer
first of all to anxiety, apathy and depression that are fre-
quently encountered in de novo drug-naïve PD patients
[54] and reverted when dopamine replacement therapy
(DRT) is introduced [66, 81]. Neuropsychiatric signs also
encompass neuropsychiatric fluctuations (NPF), Impulse
control disorders (ICDs) and related disorders, and psych-
osis that are frequently observed along the progression of
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ioural disorders in PD have been conceptualized as a
hypodopaminergic behavioural syndrome where apathy
predominates, hyperdopaminergic behavioural syndrome
which includes ICDs and other behavioural addictions,
and non-motor fluctuations [2, 75] that together, define
two opposite sides of one behavioural spectrum [81]. ICDs
and related behaviors comprise a set of behaviors charac-
terized by both impulsive and compulsive aspects. Impul-
sive aspects refer to an inability to resist an impulse or
inappropriate drive despite harmful consequences for pa-
tients and their relatives, whereas compulsive aspects refer
to the intrinsic repetitive nature of these behaviors that in-
dicate a lack of self-control [100]. As with drug addictions,
ICDs and related disorders are underpinned by one com-
mon pathophysiological mechanism that consists in hy-
persensitization of reward circuits and heightened ventral
striatal dopamine release in response to reward-related
cues [52]. Thus, from a clinical perspective, pathological
gambling has been removed from ICDs in DSM-IVle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
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tions in DSM-V. However, DSM-V nosology of ICDs and
related disorders remains unclear and shared between
ICDs and behavioural addictions. Based on the patho-
physiology of those disorders, we prefer the label of be-
havioural addictions to describe the full spectrum of
hyperdopaminergic behaviours [6, 52]. Dopamine dysreg-
ulation syndrome (DDS) is a specific entity characterized
by compulsive use of levodopa irrespective of
motor-fluctuations and dyskinesias, along with behav-
ioural changes from the spectrum of behavioural addic-
tions [30, 47]. Although DDS was initially thought to be
driven by the severity of non-motor OFF symptoms such
as pain or anxiety, a recent study argued that the
non-motor “ON-drug” state was the driving force that en-
hance compulsive drug intake [20]. Thus, patients who
developed DDS might be seeking “ON-drug” euphoria ra-
ther than preventing “OFF-drug” dysphoria [20]. Behav-
ioural addictions result from complex interaction between
individual risk factors, PD pathology and DRT. The pur-
pose of the present review is to delineate the neurobiology
and the clinical spectrum of behavioural addictions that
are still under recognized despite their potential devastat-
ing consequences for patients and their relatives [69].
Neurobiology
Brain systems involved
The mesolimbic dopaminergic system consisting of the
dopaminergic ventral tegemental area (VTA) and the
ventral striatum, with the nucleus accumbens as most
prominent player, has been frequently dubbed as the
brain’s reward system [38]. This view, however, falls con-
siderably short of the complexity of the brain areas in-
volved in guiding goal directed behavior [34, 36]. For
example, Kelley [40] has compiled a complex network of
brain areas including the mesolimbic dopaminergic sys-
tem from animal work on ingestive behavior. Interest-
ingly, we have been able to detect most of these brain
areas in a neuroimaging study involving a gambling task
([11]; Fig. 1a). Inspection of this network suggest that
the prefrontal cortex might act as a control instance. In-
deed, ICDs in PD and in other conditions might be con-
ceptualized as resulting from an imbalance between the
craving for a reward and the inability to suppress this
behavior, whenever it might not be appropriate.
Intertemporal choice task
To assess the interplay of the brain areas depicted in Fig.
1 and their involvement in ICDs in PD, the intertem-
poral choice paradigm has been used which involves
choices between two rewards available at different times.
Usually, this is an immediately available smaller reward
and a larger reward which can be obtained only after a
delay. A multitude of studies in humans and animalssuggests that future are discounted in a quasi-hyperbolic
or hyperbolic fashion [28, 57], the latter of which can be
captured by the following function:
V ¼ A
1þ kD
where V is the present value of the delayed reward A
after a delay D, and k is the delay discount rate. A
greater delay discount rate indicates a steeper discount
function, i.e. a more pronounced devaluation of future
rewards. The neural underpinnings of intertemporal
choice have been investigated using neuroimaging studies
in humans and neurophysiological recordings in primates
and other species [7, 23, 24, 35, 37, 55, 58, 59, 68, 109].
One of the earliest neuroimaging studies of intertemporal
choice proposed two neural systems in intertemporal
choice [58, 59]: a beta system, comprising limbic struc-
tures thought to place special weight on immediate re-
wards, whereas prefrontal cortical structures, the delta
system, are thought to mediate deliberate, patient choices.
Alternatively, a unitary system comprising medial pre-
frontal and posterior cingulate cortex and the ventral stri-
atum has been proposed which represents and compares
the values of both, immediate and delayed choices (Kable
and Glimcher, 2007Peters and Büchel, 2009). Volkow and
Baler [93] have recently pointed out that decisions for im-
mediate or delayed rewards (in their words “now” or
“later” processes) are differentially modulated by dopa-
mine signals. Whereas decisions for delayed rewards re-
quire steady, tonic firing of dopaminergic neurons in
striatal and prefrontal regions to sustain effort, “now” pro-
cesses are thought to be dependent on fast, burst-like fir-
ing of dopaminergic neurons in ventral and dorsal striatal
regions, which drives the desire to attain and consume the
stimulus. This model is supported by brain imaging stud-
ies [27, 94].
Voon et al. [96] employed an intertemporal choice task
in PD patients with ICDs, PD patients without clinically
apparent ICDs and healthy controls. Patients were tested
on and off dopamine replacement therapy. Of note, the
task used by Voon et al. [96] employed rather delays (7–
28 s) and real-time consummatory feedback during the
task rather than long delays of weeks and months used
in most behavioral economics tasks [41]. A group by
medication interaction effect was revealed, reflecting a
steeper discounting curve (i.e. more impulsive choice) in
PD patients with ICDs when on dopamine agonist ther-
apy. No medication effect was found in PD patients
without ICDs. By contrast, Milenkova et al. [60] found a
steeper discounting for PD patients in a monetary inter-
temporal choice task employing delays of up to 6
months. The PD patients in that study were not having
clinically apparent ICDs. In a small study of 7
Fig. 1 a Scheme of the reward valuation network as derived from a neuroimaging study by Camara et al. [11] (orange boxes, black arrows)
embedded in a wider motivation/learning circuit (gray boxes and arrows). The wider network is based on Kelley et al. (2004), omitting unspecific
hypothalamic/thalamic projections. b Model of intertemporal choice behavior as proposed by Volkow and Baler [93]. The regions colored in red are
considered to support decisions for later, larger rewards (“LATER”), whereas the green areas support decisions for immediately available rewards
(“NOW”). Regions depicted in blue modulate intertemporal choice behavior by integrating different information (described in black lettering). Please
note, that tonic dopamine (DA) signals are thought to favor LATER rewards by influencing frontal regions. By contrast, phasic DA signals drive
decisions towards choosing the immediately available reward (NOW). Regions: dorsolateral prefrontal cortex (dlPFC), medial PFC (mPFC), ventromedial
PFC (vmPFC), orbitofrontal cortex (OFC), anterior cingulate cortex (ACC), nucleus accumbens (NAcc). c Illustration of the role of phasic and tonic
dopaminergic projections (after [32]): The Nacc serves as an integrator of afferent inputs from frontal and limbic regions. Of note, the input from the
PFC is regulated by dopaminergic input from VTA via presynaptic D2 receptors, with D2 receptor stimulation resulting in an inhibition of PFC input to
the Nacc. The presynaptic neurons are stimulated by tonic dopamine neuron firing leading to low tonic levels of dopamine. High-amplitude, phasic
dopamine signals on the other hand lead to D1 receptor activation that potentiates the hippocampal input to the NAcc
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gene who later developed PD, Szamosi et al. [85]
found a similar delay discounting behavior during the
presymptomatic stage in carriers compared to
non-carrier control participants. After the develop-
ment of PD a significantly steeper discounting (i.e.,
more impulsive decisions) were seen in the subjects
with SNCA duplications after the initiation of dopa-
mine replacement therapy. Again, these patients did
not exhibit overt ICDs. It thus appears that impulsive
choices are more abundant even in PD patients with-
out ICDs.
Dopamine agonists lead to a blunted response of the
reward system
Clinical experience and large epidemiological studies
(e.g., [102]) point to dopamine agonists as predisposing
factors for the development of ICDs in PD. The question
arises, how these drugs may modulate responses of the
reward system. Importantly, Schott et al. [79] coulddemonstrate that reward-related ventral striatal dopa-
mine release predicted functional magnetic resonance
imaging activations in the ventral striatum during re-
ward anticipation. Knutson and Gibbs [42] suggested
that dopamine released in the Ncl. Accumbens (NAcc)
changes the postsynaptic membrane potential by activat-
ing dopamine D1 receptors which in turn increases the
local blood oxygen level dependent (BOLD) signal de-
tected by fMRI. Thus, NAcc activity in response to pos-
sible rewards may be regulated by dopamine
autoreceptors D2 and D3, which inhibit dopamine syn-
thesis and/or release [22]. Dopamine D2/D3 receptor ag-
onists then decrease NAcc dopamine release and reduce
the incentive effect of rewards. Consistent with these
predictions, we could demonstrate a blunted response to
reward delivery in a gambling task in normal partici-
pants after a single dose of pramipexole ([74], Fig. 2a).
Also, activation of the ventral striatum / NAcc was
found reduced during anticipation of a reward in a mon-
etary incentive delay task [106]. In Parkinson’s disease,
Fig. 2 a FMRI results from a gambling task in young healthy participants. Axial slices show greater activation for win compared to loss trials in
the ventral striatum and midbrain after placebo and pramipexole. A single dose of pramipexole (0.5 mg) resulted in a marked attenuation of
reward based activations. After data presented in Riba et al. [74]. b FMRI results from a monetary incentive delay task. Shown are core regions of
the reward processing network for the contrast “expectation of reward > expectation of no-reward”. Please note that PD patients on dopamine
agonist treatment show a marked attenuation of activation compared to healthy controls and PD patients off medication (unpublished data from
Ye and Münte obtained from 17 PD patients and 17 matched control participants). c Nucleus accumbens connectivity during reward expectation
in a monetary incentive delay task. Regions functionally connected with the NAcc during reward expectation under placebo and pramipexole.
Arrows indicate the frontal cortex (blue) and the insular cortex (green). The scheme at the bottom presents the connectivity patterns under
placebo and pramipexole. The dopamine agonist therapy results in a shift of connectivity (less connectivity between NAcc and frontal cortex,
greater connectivity between NAcc and insular cortex)
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patients on dopaminergic agonist therapy but not pa-
tients off therapy (Fig. 2b). In addition to changing the
response in the NAcc, dopaminergic agonist therapy also
leads to profound changes of connectivity: Connections
between the dorsolateral prefrontal cortex and the NAcc
are downregulated after pramipexole, whereas connec-
tions between the insula and the NAcc are upregulated
([11]; Fig. 2c). Van Eimeren et al. [91] used H2
15O PETbefore and after administration of 3 mg apomorphine to
assess regional cerebral blood flow during a gambling
task in PD patients with pathological gambling and PD
patients without ICDs. Indeed, gamblers showed a sig-
nificant DA-induced reduction of activity in reward re-
lated brain areas, corroborating the previously
mentioned results. PD patients with ICDs have also been
studied using radioligands binding to dopamine recep-
tors. For example, Stark et al. [84] used [18F] fallypride, a
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with and without ICDs. Patients with ICD had re-
duced binding potential in the ventral striatum and
ICD symptoms positively correlated with midbrain
D2/3 receptor binding potential. The authors sug-
gested that ICDs in PD are associated with reduced
ventral and dorsal striatal D2/3 expression, which
may account for their differential response to dopa-
mine agonist therapy.
Genetics
As not all PD patients on DRT develop behavioral addic-
tions / ICD, the question arises whether a specific genetic
background disposition might contribute to such behav-
iors. Multiple studies have been conducted to pinpoint sin-
gle nucleotide polymorphisms (SNPs), mostly in genes
related to the function of monaminergic transmitter sys-
tems, as either conducive or protecting. Evidence suggests
a role of SNPs in genes involved in dopamine metabolism
(COMT, DAT), dopamine receptors (DRD1, DRD2, DRD3,
DRD4), serotonin receptors (HTR2A) and transporters
(5HTT), and glutamate receptors (GRIN2B) [48, 49, 108],
even though some studies also were negative [90]. These
studies suggest that genetical factors play an important role
in behavioral addictions in PD. However, as in other cogni-
tive domains (e.g., executive functions, [45]) each SNP may
account only for a small portion of the variance.
Therefore, a recent prospective multigene study by
Kraemmer et al. [44] is of utmost importance. In this
study, de novo drug-naïve patients (n = 276) with PD
who had no behavioral addictions / ICD at the initial
measurement were followed for 3 years. During this
period 238 patients started DRT of whom 40% were tak-
ing a DA. During the follow-up, 19% of the patients de-
veloped behavioral addictions / ICD as determined by
the Questionnaire for Impulsive-Compulsive Disorders
in PD (QUIP). Heritability of such behaviors was esti-
mated to be 57% by restricted maximum likelihood ana-
lysis on whole exome sequencing data. Importantly, the
occurrence of behavioral addiction in a given patient
could be predicted with 87% accuracy in patients receiv-
ing DA when a model contained clinical data and the ge-
notypes of 13 candidate variants in the DRD2, DRD3,
DAT1, COMT, DDC, GRIN2B, ADRA2C, SERT, TPH2,
HTR2A, OPRK1 and OPRM1 genes. This compared to
71% accuracy based on clinical data alone. A backward
stepwise regression analysis identified age, male sex,
dopamine replacement therapy and ADRA2C, DRD2,
DDC, HTR2A and OPRK1 genotypes as significant pre-
dictors of behavioral addiction / impulse control disor-
ders. Taken together, this suggests that it might be
possible in the future to predict which patients are vul-
nerable to behavioral addictions prior to initiation of DA
therapy.Beyond the dopaminergic system
A number of animal studies [4, 21] as well as work in
human PD patients [31, 92, 98] have suggested a role for
noradrenaline in impulsivity and inhibitory functions in
addition to the undisputed function of the dopaminergic
system. These findings have triggered studies using the
selective noradrenaline reuptake inhibitor atomoxetine
in PD to modulate the response inhibition system [10,
39, 73, 105, 107]. For example, Ye et al. [105] employed
the stop-signal task in PD patients and control partici-
pants and found that the former had longer stop-signal
reaction times as well as less stop-related activation in
the right inferior frontal gyrus in fMRI accompanied by
weaker functional connectivity between this region and
the striatum. These changes in PD were normalized by
atomoxetine. Rae et al. [73] using the same task pro-
posed that atomoxetine acts by increasing sensitivity of
the inferior frontal gyrus to afferent inputs from the
pre-supplementary motor cortex. Warner et al. [98]
reviewed the evidence for an effect of atomoxetine in
clinical symptoms of impulsivity, risk taking, and global
cognition. The few available studies indeed suggest a
beneficial effect.
Clinical features
Epidemiology
Prevalence of ICDs and related behaviors ranged from
13,6 to 33% according to studies [1, 5, 95, 97, 102]. This
variability is partly related to declarative and cultural
bias, clinical scales applied to asses ICDs, as well as
methodological issue: cross sectional versus prospective
studies, the clinical spectrum considered (i.e. the four
ICDs strictly speaking or the whole hyperdopaminergic
behavioral spectrum) and differences in populations in-
vestigated (de novo PD, surgical candidates or advanced
PD). All together, these studies pointed out the close
interaction between individual susceptibility, DRT and
PD pathology in the emergence of behavioral addictions.
Patients with ICBs and related behaviors were more
likely to have anxious mood phenotype, more motor
fluctuations, and to be younger [95, 97, 102]. Those re-
sults have been confirmed by the prospective ICARUS
study where ICD positive patients were more likely to be
male, younger at PD onset, have a longer disease dur-
ation, depressive symptoms and poorer quality of life [1].
As mentioned above, some recent genetic studies ar-
gued for a genetically determined risk factors for devel-
oping ICDs [17]. Polymorphisms in genes coding for
dopamine metabolism, serotonine and glutamate recep-
tors have been particularly studied [17]. Moreover, a
large prospective study based on a candidate gene multi-
variable panel identified OPRK1 (involved in the opioid
system) and DDC (dopamine system) polymorphisms as
risk factors for ICDs and related disorders [44].
Béreau et al. Neurological Research and Practice             (2019) 1:9 Page 6 of 11Dopamine agonist (DAs) exposure is the main risk fac-
tor of developing ICDs [100]. Since the DOMINION
study, a drug class relationship has been postulated as
DAs was associated with 2 to 3,5-fold increased odds of
having an ICDs [102]. Those results were confirmed by
further prospective studies [5, 18]. Recently, a longitu-
dinal study conducted in 411 patients showed that life-
time average daily dose and duration of treatment were
independently associated with ICDs with significant
dose-effect relationships [18]. DA that exhibit a higher
selectivity for D2/3 receptors mainly expressed within
the mesocorticolimbic pathway, play a crucial role in the
emergence of behavioral addictions [33, 81]. Further-
more, the pulsatility of DRT involved in sensitization of
D1 receptors within the nigrostriatal pathway and dyski-
nesias [70], may be implicated as well in sensitization of
D3 receptors within the mesocorticolimbic pathway and
behavioral addictions [20, 77, 81]. Short acting, high po-
tency DAs but also levodopa are associated with pund-
ing and DDS [26, 47].
A case-control study comparing de novo untreated PD
patients and unmatched healthy controls investigated
the question whether PD itself could confer an altered
risk for ICDs and related behaviours [104]. No signifi-
cant difference between the two groups has been shown
regarding the prevalence of any ICDs valued at about
20%. The conclusion of this study was that PD alone,
did not seem to provide an increased risk of developing
ICDs [104]. However, once treatment is started, PD pa-
tients who have a more severe dopaminergic denervation
as shown by DAT-scan are at higher risk to develop
ICD. Thus, interaction between PD pathology and dopa-
mine replacement therapy play a crucial role in the de-
velopment of ICDs [82].
Behavioral addictions are more frequent in advanced
PD and surgical DBS candidates [8, 25, 52]. Interestingly,
advanced PD and surgical DBS candidates had higher
disease duration, higher levodopa and agonist equivalent
daily dose, and higher proportion of motor and
non-motor fluctuations [8, 25, 52]. Moreover, multiple
behavioral addictions have been frequently reported [25].
In the ALTHEA study, behavioral addictions were ob-
served in 55% of PD patients with dyskinesias and motor
complications [8]. Furthermore, frequency of ICDs
symptoms was much higher in patients with severe dys-
kinesias compared to patients with mild to moderate
dyskinesias. Dyskinesias occur in patients with high
L-dopa sensitivity and result from a treatment, that is
too pulsatile. Indeed, fractionating L-dopa or adminis-
tering L-dopa with continuous perfusion can reverse
dyskinesias and ICD [14]. Taken together, these obser-
vations support that pulsatility of DRT is another im-
portant common risk factor for both dyskinesia and
ICD [8].Neuropsychiatric fluctuations (NPF), that reflect meso-
corticolimbic denervation along the progression of PD
pathology, are associated with the emergence of behav-
ioral addictions such as DDS in surgical DBS candidates
[20], as well as post-operative withdrawal syndrome in
post-operative DBS patients [86]. These results support a
more complex interaction between DRT and PD pathology
in the emergence of behavioral addictions. While
non-motor fluctuations and ICDs are markedly reduced
during the post-operative state in DBS PD patients [52, 53],
DBS PD patients frequently develop post-operative apathy
unmasked by the decrease in DRT, and related to
desensitization of a more severe denervated dopaminergic
and serotonergic mesocorticolimbic pathways [54, 86].
Thus, apathy and behavioral addictions may be considered
as the Yin and Yang of dopamine dependent behaviors [81].
Clinical spectrum
The whole behavioral clinical spectrum illustrates the
relation between personality, dopamine and behaviors
[19, 51]. While PD patients frequently exhibit harm
avoidance and introspective traits that refers to baseline
personality traits [88], they also frequently develop
apathy, anhedonia, depression, and anxiety during the
premotor stage of the disease, the so-called “hypodopa-
minergic behavioural spectrum” [66, 80]. Conversely,
later in the disease course, patients which are prone to
develop ICDs and related disorders, the so-called “hyper-
dopaminergic behavioural spectrum”, frequently exhibit
novelty seeking, and risk-taking personality traits, the
exact opposite of the premorbid pattern mentioned
above [19, 51].
The “honey moon” defines a well-being state for pa-
tients, where motor and non-motor signs are reverted
by DRT [2]. The psychotropic effect of dopaminergic
drugs might be the main factor that reflects this
well-being feeling expressed by patients. During the
motor and non-motor fluctuations state, neuropsychi-
atric fluctuations (NPF) are characterized by dysphoria,
sadness, indifference, vulnerability in OFF state, and eu-
phoria, pleasure, self-confidence in ON state [56]. NPF
might play the driving force that promote behavioral ad-
dictions [20].
The hyperdopaminergic spectrum encompasses the
four ICDs originally described, namely pathological gam-
bling, hypersexuality, compulsive buying and compulsive
eating as well as other behavioral addictions such as
hobbyism, punding, walkabouts, hoarding, and DDS
[100]. Pathological gambling predominates in men and
is characterized by a preference for casinos and slots
machine that can lead to financial problems. PD patients
with hypersexuality had increased libido, increased de-
sire for frequent sexual intercourse, as well as compul-
sive use of sex lines telephone, internet pornography, or
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ences and paraphilia have been more rarely reported
[83]. Compulsive buying usually affects women and con-
sists in an irrepressible and repetitive impulse to buy un-
necessary items [16, 43]. Compulsive eating is defined by
a persistent binge eating that occurs during day or night,
with excessive and uncontrollable consumption of food
[63]. Hobbyism that recently arose among the hyperdo-
paminergic behavioral spectrum is characterized by per-
petual repetitive actions such as reading, internet
browsing, working on projects, or painting [100]. Some
other patients may also exacerbate or develop a creative
art work [50]. Hoarding refers to a compulsive collecting
of objects without objective value. In such cases, it can
lead to unsanitary living conditions [64]. Punding is
characterized by stereotypical motor behaviors such as
manipulations, examinations, collecting, and other pur-
poseless repetitive actions, that are frequently accom-
panied by dyskinesias and dopamine dysregulation
syndrome (DDS), suggesting a common pathophysio-
logical mechanism [26]. DDS is a clinical entity that cor-
respond to an addiction to DRT combined with mood
fluctuations and other behavioral addictions [30, 47].
Addiction to dopamine medications manifested by a
compulsive craving and self-medication with increasingly
dose of dopamine irrespective of motor state and dyski-
nesias [30, 47]. This DRT addiction, can lead to the
full-blown DDS, where mood fluctuations and other be-
havioral addictions such as punding are present [30, 47].
Clinical tools
Different clinical tools have been validated for screening
and/or diagnosis of ICDs and related behaviors. The
Minnesota Impulsive Disorders Interview (MIDI) one of
the first scale reported is not specifically addressed to
PD patients [15, 16]. Other scales dedicated to PD have
been developed: The Questionnaire for Impulsive Com-
pulsive Disorders in Parkinson’s disease (QUIP) for
screening [101] and the rating scale version of the QUIP,
namely the QUIP-RS [103]. The Ardouin scale for be-
havioral assessment is based on a semi-structured inter-
view that encompasses the whole spectrum of behavioral
spectrum from hypo- to hyperdopaminergic syndromes
as well as non-motor fluctuations [2, 75]. Non-motor
fluctuations can be specifically addressed and quantified
with the Neuropsychiatric Fluctuations Scale (NFS), a re-
cently developed tool [78].
Management of ICDs
Management of ICDs and related disorders remains
challenging. Careful interview and education of patients
and their relatives about risk factors: non-motor ON
[20], dyskinesia [95, 97], DA intake (5 years cumulative
risk of 50%) [18] is a crucial step before starting DRT[6]. Detection and evaluation of early changes in behav-
iors is mandatory when DRT is started. This consists of
screening for benign changes along the behavioral
spectrum from hypodopaminergia to hyperdopaminergia
as well as neuropsychiatric fluctuations, using dedicated
clinical scales [6].
When ICDs occur, practical management will be
adapted, taking into account severity of ICDs and impact
on QOL, rather than the semiology itself. Basically, DA
dose reduction, fractionation of L-Dopa must be first con-
sidered. Importantly, clinicians have to bear in mind that
desensitization of the mesolimbic dopaminergic system is
prolonged and may take weeks or months [12, 13, 52, 86].
In such cases, adjunction of clozapine, amantadine or nal-
trexone may be helpful. Moreover, in cases of ICDs associ-
ated with DDS and severe motor fluctuations in younger
PD patients, STN-DBS may represent an interesting
therapeutic option.
DA should be carefully tapered below the individual
threshold of inducing behavioral addictions, while avoid-
ing the appearance of dopamine withdrawal syndrome
[72]. Continuous delivery of D2/D3 agonists using ex-
tended release formulations or transdermal administra-
tion should be preferred [29], but overall all available
dopamine agonists are very similar in effect. Apomorph-
ine is the only available exception, as this agonist has a
D1/D2 profile similar to endogenous dopamine with ef-
fects similar to L-dopa. Constant delivery of apomorph-
ine with subcutaneous infusion using a mini-pump is a
good alternative [3, 89]. Although typically not men-
tioned in the literature as evidence based studies are
lacking, L-Dopa fractionation that is indicated when
motor complications and dyskinesia occur, should also
be considered for the management of non-motor com-
plications and behavioral addictions as the first approach
in patients on L-dopa. Although studies are lacking,
based on expertise this is the easiest and most effective ap-
proach. Efficacy of non-pulsatile administration of L-dopa
has been shown in a prospective observational study of 66
consecutive PD patients treated with levodopa-carbidopa
intestinal gel infusion. Catalan et al. [14] found a signifi-
cant 64,4% reduction of ICDs symptoms compared to
baseline over the 6-month’s follow-up.
Clozapine, an atypical neuroleptic that improve levo-
dopa induced psychosis and dyskinesia, has been re-
ported to reduce ICDs symptoms in patients in which
dopamine dose reduction did not improve those symp-
toms [9, 76]. Conflicting results have been shown with
amantadine, a glutamate receptor antagonist. Although
one small double blind crossover study reported im-
provement in pathological gambling in PD patients [87],
the DOMINION study highlighted a positive correlation
between amantadine and ICDs, even when taking into
account levodopa and DA dosages [102]. One small
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showed some evidence for an effect [67]. This effect was
corroborated by small clinical trials in other,
non-PD-related behavioral addictions [61]. Accordingly,
additional data are needed to support the use of clozapine,
amantadine or naltrexone for the treatment of ICDs and
related disorders. STN-DBS is a well-established
treatment for PD patients with motor complications.
Moreover, drastic dopamine dose reduction following
STN-DBS is responsible for substantial decrease of dys-
kinesia. Recently, a randomized controlled study compar-
ing STN DBS plus medical therapy and best medical
treatment over a period of 2 years, demonstrated a better
behavioral outcome with STN DBS plus medical therapy
compared to best medical treatment [53]. Finally, the po-
tential usefulness of cognitive behavioral therapy (CBT)
for ICDs and related disorders has been highlighted in
one randomized study [65].
Discussion and outlook
Behavioral addictions / ICDs present a major problem in
the clinical management of PD. Research over the past
20 years has revealed that occurrence of such behaviors
is by no means an exceptional event [102] and that ICDs
are but one aspect of a larger spectrum of hyperdopami-
nergic behavioral disorders that also include punding
and dopamine dysregulation syndrome [6, 30, 47, 52].
Both dopamine agonists with a high affinity for the
mesolimbic D3 receptor and pulsatile treatment with
L-dopa contribute to ICD in interaction with the severity
of the disease explaining that ICD can appear after many
years of treatment and increase in DRT is not a
mandatory prerequisite. Clinicians have to screen sys-
tematically for behavioral side effects of dopaminergic
treatment using specific tools from initiation of therapy
to the most advanced stages.
Neuroimaging approaches have only begun to unravel
the neural underpinnings of these behaviors. A blunted
response of the reward system comprising the ventral
striatum as a core structure and a changed connectivity
pattern are induced by dopamine agonists [11, 74, 106].
This shifts the balance towards more impulsive, risk
seeking behaviors as evidenced by steeper discounting of
future rewards seen most prominently in PD patients
with ICDs [96]. A shift from the LATER system (in the
sense of [93]) driven by tonic dopamine signals to the
NOW system supported by phasic dopaminergic trans-
mission underlies this preference for more impulsive be-
havior. These findings might be instrumental in the
development of therapy strategies. Moreover, the finding
of a substantial genetic contribution, i.e. predisposition,
to the development of ICDs [44] might allow to taylor
the dopamine replacement therapy according to the in-
dividual genetic profile.Abbreviations
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